Additional file 1 of Quantitative proteomics by iTRAQ-PRM based reveals the new characterization for gout

Additional file 1: Table S1. Details of differentially proteins. Table S2. The mapped signaling pathways of the differentially expressed proteins between AG and control. Table S3. The mapped signaling pathways of the differentially expressed proteins between RG and control. Table S4. The mapped signaling pathways of the differentially expressed proteins between AHU and control. Table S5. The mapped signaling pathways of the differentially expressed proteins between AG and AHU. Table S6. Sheet 1. Information about all candidate peptides of the protein to be validated. Sheet 2. A list of peptides from DDA analysis. Table S7. OLPS-DA VIP score more than 1. Figure S1. Example chromatogram of peptide segments. Supplementary Figure S2. Serum profles of DEPs for the healthy controls (CTL), the patients with acute gout (AG), remission of gout (RG) and asymptomatic hyperuricemia (AHU).附加文件1：表S1 差异表达蛋白质详情。表S2：急性痛风（Acute Gout, AG）与对照组间差异表达蛋白的映射信号通路。表S3：痛风缓解期（Remission of Gout, RG）与对照组间差异表达蛋白的映射信号通路。表S4：无症状高尿酸血症（Asymptomatic Hyperuricemia, AHU）与对照组间差异表达蛋白的映射信号通路。表S5：急性痛风（AG）与无症状高尿酸血症（AHU）间差异表达蛋白的映射信号通路。表S6：工作表1：待验证蛋白质的全部候选肽段信息；工作表2：数据依赖性采集（Data-Dependent Acquisition, DDA）分析得到的肽段列表。表S7：OLPS-DA变量重要性投影（VIP）得分大于1的条目。图S1：肽段色谱图示例。补充图S2：健康对照组（Healthy Controls, CTL）、急性痛风（AG）患者、痛风缓解期（RG）患者及无症状高尿酸血症（AHU）患者的差异表达蛋白（Differentially Expressed Proteins, DEPs）血清谱图。